CareDx develops diagnostic tests and digital tools for solid organ transplant patients, with a focus on non-invasive monitoring of graft health. Flagship offerings include donor-derived cell-free DNA assays such as AlloSure and gene-expression tests like AlloMap, used to help detect rejection risk without routine invasive biopsies. Customers are transplant centers, clinicians and patients across kidney, heart and other organ pathways.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 86.7 | — | -8.6 | — |
| Q3 2025 | 100.1 | — | 1.7 | — |
| Q4 2025 | 108.4 | — | -4.1 | — |
| Q1 2026 | 117.7 | — | 2.8 | — |
| Q2 2026 | 131.9 | 52.2% | 110.6 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: First Financial Bancorp. (FFBC), Amylyx Pharmaceuticals, Inc. (AMLX), First Advantage Corporation (FA), Webull Corporation (BULL), Acadia Pharmaceuticals Inc. (ACAD), National Beverage Corp. (FIZZ)